A clinical study showed that Soticlestat, when added to standard treatment, tended to reduce convulsive seizures in children and young…
Margarida Maia, PhD
Margarida is a biochemist (University of Porto, Portugal) with a PhD in biomedical sciences (VIB and KULeuven, Belgium). Her main interest is science communication. She is also passionate about design and the dialogue between art and science.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Margarida Maia, PhD
Problems with sleep and body temperature regulation in Dravet syndrome are linked through the hypothalamus — the part of the…
Stoke Therapeutics plans to meet with the U.S. Food and Drug Administration (FDA) before the end of this year…
In a mouse model study of Dravet syndrome, males were seen to be more vulnerable to abnormal heartbeats and…
Stoke Therapeutics’ zorevunersen, a treatment that addresses the genetic cause of Dravet syndrome, continues to reduce the frequency…
Nine months of treatment with bexicaserin (LP352), an investigational oral small molecule from Longboard Pharmaceuticals, more than halved the…
Encoded Therapeutics has been cleared by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to begin clinical testing…
Health Canada has approved Epidiolex (cannabidiol) as an add-on treatment for seizures in adults and children, ages 2 and…
During clinical trials, side effects are more common in people who use cannabidiol (CBD) to treat some forms of epilepsy,…
Longboard Pharmaceuticals has finished enrolling patients in PACIFIC, its Phase 1b/2a clinical study of LP352, an investigational oral serotonin…